Friday, October 18, 2019
News
NEWS HOME
»
PRESS RELEASES

Financial year 2018: Boehringer Ingelheim grows and invests
  SocialTwist Tell-a-Friend  
   


Date: 17-04-2019 3:25PM
Source: Boehringer Ingelheim
Category: Business/ Finance, Financial Analyst & Investors, Pharmaceutical, General, Science & Research, Healthcare & Biotechnology
Location: Ingelheim, Germany

Business Wire India

The research-driven pharmaceutical company Boehringer Ingelheim ended 2018 with net sales of 17.5 billion euros. Adjusted for currency effects, as well as one-off effects due to the asset swap with Sanofi in 2017, net sales grew by 4 per cent. At 3.2 billion euros (+2.8%), R&D expenses increased to 18.1 per cent of annual net sales.

In the process, the company has focused on specific therapeutic areas. “We want to make a significant contribution towards a superior treatment of cancer,” says Hubertus von Baumbach, Chairman of the Board of Managing Directors. “In addition, we are conducting research, among others, into fibrotic, metabolic and immunological diseases. Our research pipeline is well-filled.”

At almost 1 billion euros (+9%), investments in tangible assets were higher than ever before. Operating income again amounted to 3.5 billion euros (- 0.4%), while Group profit after tax increased to 2.1 billion euros. “In 2018, the return on net sales increased from 19.3 to 19.8 per cent, while our equity ratio rose from nearly 38 per cent to 40 per cent. Thus we are also a very healthy company from a financial point of view,” remarks Michael Schmelmer, Member of the Board of Managing Directors responsible for Finance.

The average number of employees in all regions increased slightly to a total of 50,370 (+2%).

Human pharmaceuticals – strong portfolio

At 12.6 billion euros, human pharmaceuticals contributed to 72 per cent of total net sales in 2018. Foreseeable declines in net sales, due to expiring patents for innovative medicines, were more than compensated for, this business thereby achieving currency-adjusted growth of 5.1 per cent. Revenues from the global licensing business were lower than in the previous year and have reduced the overall rate of growth in this business area to 3.3 per cent.

As in previous years, the respiratory medicine SPIRIVA® achieved the highest net sales contributions with 2.4 billion euros (-11.4% currency-adjusted), followed by the type-2 diabetes medicine family JARDIANCE®, including SYNJARDY® and GLYXAMBI®, with 1.8 billion euros (+52.5% currency-adjusted), the anticoagulant PRADAXA® with 1.5 billion euros (+7.0% currency-adjusted), the type-2 diabetes medicine TRAJENTA® with 1.4 billion euros (+9.0% currency-adjusted), as well as OFEV® for the treatment of idiopathic pulmonary fibrosis (IPF), with 1.1 billion euros (+28.7% currency-adjusted).

At 2.8 billion euros, research and development investments in human pharmaceuticals corresponded to a 22.1% share of human pharmaceuticals’ net sales. For the total of 90 projects in all phases of the research process, the goal is for 75 per cent of them to be either the first molecules in their active ingredient class or the first in a new therapeutic area. In oncology, the focal points are cancers of the lung, stomach and intestine, while in fibrotic diseases the focus is on systemic scleroderma with interstitial lung disease. In metabolic diseases, non-alcoholic steatohepatitis is the main focus of research. In immunology, research is giving attention to chronic inflammatory diseases of the skin and intestine. Other projects address diseases of the central nervous system, such as Alzheimer’s and schizophrenia, obesity and retinopathy.

Animal health – Technical integration completed

In animal health, our focus is on innovative vaccines, antiparasitic medicines and further therapy solutions for livestock and pets. In 2018, the three antiparasitic medicines NEXGARD®, FRONTLINE® and HEARTGARD®, plus the vaccine INGELVAC CIRCOFLEX®, were the four best-selling products. Net sales of 4 billion euros represented 23 per cent of total net sales.

In the second year of the Merial transaction, this business has thereby achieved significant net sales growth, with a currency-adjusted rate of 5.6 per cent, while simultaneously undertaking integration efforts. “We have focused on providing our customers with continuous supply from day one. As a result, we have achieved good growth and the technical integration is successfully completed,” says Hubertus von Baumbach. The innovation potential in animal health, where it interrelates with human pharmaceutical research, deserves particular attention.

Biopharmaceutical contract manufacturing maintains lead position

The biopharmaceuticals business maintained its lead position in the contract manufacturing segment in the financial year 2018 and provided 4 per cent of overall net sales. The order situation has continued to develop positively and provided for a high level of capacity utilization in biopharmaceutical production.

Outlook for 2019

For the current financial year, Boehringer Ingelheim is expecting slight growth in net sales and further intensive investment activities on a comparable basis. “In Europe alone we are planning investments of more than 3 billion euros within the next five years,” says von Baumbach. “The key precondition for this are competitive overall conditions at our European sites.”

Please click on the link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/annualresultspressconference2019



CONTACTS :

Boehringer Ingelheim
Corporate Communications
Media + PR
Matthias Reinig
55216 Ingelheim/Germany
Phone: 06132 – 77 18 48 55
Fax: 06132 – 77 6601
Email: press@boehringer-ingelheim.com

More Press Releases

The Hero Campus Challenge Returns to Nurture the Business Leaders of Tomorrow

Vakilsearch Signs MoU With the Largest Dutch Legal-Tech Company

Make Your Diwali Thrilling with RummyBaazi.com

The 46th Tokyo Motor Show 2019: Events and Programs News Update

Pioneer Cement of UAE to Develop US$200 Million Greenfield Cement Project in Georgia

FlowerAura Launches Profile Picture Worthy Bhai Dooj Gifts for 2019

Secure Your New Smartphone With Mobile Screen Insurance From Bajaj Finserv

Mavenir Confirmed as Global Leader in NFV-based IMS Solutions

Andersen Global Expands in India With Membership of Nangia Andersen LLP

Lookout App Defense Penetrates Global Markets With New Customers and Strategic Partnerships, Helping Customers Prevent Data Compromise in Mobile Apps

PTC Launches Global Event Series with FT Live to Help Industrial Enterprises Embrace Digital Transformation

Historic Conrad Hilton Bel-Air Estate Hits Market for $225 Million

NITI Aayog With Institute for Competitiveness Launches India Innovation Index 2019

Child Progress Index Released for the State of Uttar Pradesh

Infor Recognized With Frost & Sullivan’s 2019 Indian Enterprise Asset Management Solution Product Leadership Award

Logicalis Announces CEO Transition Plan

More People in Phnom Penh Living With Kidney Disease Will Have Access to Dialysis From Today

WNS Announces Fiscal 2020 Second Quarter Earnings, Revises Full Year Guidance

Berlin, Auckland and Moscow Lead Global Mobility, Study Finds

Toshiba Releases Low Capacitance TVS Diodes Suitable for ESD Protection for Thunderbolt 3 and Other High Speed Signal Lines

The World’s Appetite for Fresh Meat Is Not Slowing Down

IDEMIA Acquires X Core Technologies’ Metal Payment Card Business and Launches Smart Metal Art Offer

Moody’s Analytics Enhances RiskAuthority™ Solution to Help Banks Address Final Basel III Rules

Sonion Joins Global Qualcomm Extension Program

From the Pioneer of Mega Real Estate Fests, Square Yards, Comes Another Blockbuster for Home Buyers This Diwali - ‘Buy a Home and Celebrate Diwali at Akshay’s Home’

Heilind Leading Supplier TE Connectivity Introduced Industrial Machinery Sensors

Key Trends Driving NAND Flash Memory Market in India

NIIT Recognised as Vocational & Skill Development Training Institute at Franchise Awards 2019

Johns Hopkins Center for Health Security, World Economic Forum and Bill & Melinda Gates Foundation Host Pandemic Exercise and Livestream

Electronics Maker Presents Heilind Asia with the “Best Connectors and Electromechanical Products Distributor Award”

Mavenir Launches Fully Virtualized 4G/5G OpenRAN Solution

Murray Energy Corporation Extends Forbearance Agreements with its Lenders and Elects Not to Make Interest Payments to Noteholders

Make Your Home Festival-Ready With Personal Loan for Home Renovation From Bajaj Finserv

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
MoS Home G Kishan Reddy to visit NE stat...
Are data localisation norms in sync with...
Delhi's air pollution is public health e...
If you want to give Bharat Ratna, then g...
Manmohan Singh's statement on Savarkar w...
INX media case: CBI files chargesheet in...
More...    
 
 Top Stories
Arjun Kapoor: I've been a fan of ch... 
England rope in Jeetan Patel as bow... 
China's GDP grew at lowest rate sin... 
SC orders transfer of NRC state coo... 
Trump hails ceasefire agreement wit... 
Facebook now 'fifth estate', take i... 
Rahul to replace Sonia as speaker a... 
Manmohan Singh tones down Cong line...